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Cancer represents one of the main causes of human death in developed countries. Most 
current therapies, unfortunately, carry a number of side effects, such as toxicity and damage to 
healthy cells, as well as the risk of resistance and recurrence. Therefore, cancer research is 
trying to develop therapeutic procedures with minimal negative consequences. The use of 
nanomaterial-based systems appears to be one of them. In recent years, great progress 
has been made in the field of possible use of nanomaterials with high potential in biomedical 
applications. Carbon nanomaterials, thanks to their unique physicochemical 
properties, are gaining more and more popularity in cancer therapy. They are valued 
especially for their ability to deliver drugs or small therapeutic molecules to these cells. 
Through surface functionalization, they can specifically target tumor tissues, increasing the 
therapeutic potential and significantly reducing the adverse effects of therapy. Their potential 
future use could, therefore, as vehicles for drug delivery. This review presents the latest 
findings of research studies using carbon nanomaterials in the treatment of various types of 
cancer. To carry out this study, different databases such as Web of Science, PubMed, 
MEDLINE and Google Scholar were employed. The findings of research studies chosen from 
more than 2000 viewed scientific publications from the last 15^^years were compared. 
1. Methodology of the Review 
This review is focused on the physicochemical properties of carbon nanomaterials, such 
as: active carbon, graphene, graphene oxide, carbon nanofibers, carbon nanotubes, carbon 
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nanohorns, carbon nanowalls, fullerenes, nanodiamonds, onion- like carbon), their advantages 
and potential spectrum of their biomedical use in cancer therapy in humans. The methodology 
of the choice used scientific studies from more than 2000 viewed articles from the following 
databases: Web of Science, PubMed, MEDLINE and Google Scholar based on the search 
phrases, such as: carbon nanomaterials and properties, carbon nanomaterials and 
cancer/antitumor therapy/cancer therapy, carbon nanotubes and drug delivery/target tumor 
therapy; and the main findings of various research studies from the years 2002--2017 were 
discussed. 
2. Introduction 
Cancer belongs worldwide to the leading cause of morbidity and mortality in 
humans.[1] It is predicted that by 2020, the number of new cases of cancer in the world will 
increase to more than 15 million, with deaths increasing to 12 million.[2] 
There are different cancer treatment approaches, such as: chemotherapy, surgery, 
radiation and immunotherapy.[3,4] Although chemotherapeutics are the most effective 
treatment for metastatic tumors,[5] many side effects of chemotherapy have been described, of 
which the most important are toxic side effects,[6] damage to healthy cells, and tumor 
recurrence. Moreover, the ability of cancer cells to become simultaneously resistant to 
different drugs -- a trait known as multidrug resistance -- remains a significant impediment to 
successful chemotherapy.[5] Conventional chemotherapy also presents other important 
limitation -- a lack of specificity, resulting in low concentrations of chemotherapeutic drugs at 
the tumor sites.[6] Therefore, cancer research seeks to develop treatments to minimize these 
negative side effects, moving on to the most promising cutting-edge therapies, such as gene 
therapy and nanomedicine.[3] 
Nanosize systems have pronounced advantages in cancer therapy, starting with their 
remarkable ability to accumulate at tumor sites, which is much more than in normal tissues 
due to the enhanced permeability and retention (EPR) effect of tumors. Blood vessels 
nourishing tumor tissues have larger pore sizes compared with those in healthy tissue, 
resulting in preferential tumor accumulation of nanosize anticancer drugs, increased treatment 
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efficacy and reduced systemic toxicity.[7,8] By exploiting the excellent optical and 
electromagnetic properties of nanomaterials, they are also being employed as thermal nano-
scalpels for the ablation of cancer cells. Through surface functionalization, they can be 
specifically targeted to tumorous tissue allowing for an increase in therapeutic potential and 
reduction in side effects.[9]  
Carbon nanomaterials are used for many biological[10--14] as well as biomedical 
applications, especially for advanced tumor therapy.[15--22] They have potential roles in 
delivering pharmacologic agents, diagnostic imaging agents, DNA, small interfering RNA, 
oligonucleotides, and proteins to detect or treat cancer cells.[23,24] These therapeutic 
applications were probably most described for carbon nanotubes (CNTs). 
CNTs, due to their unique physicochemical properties, have become a popular tool in 
cancer therapy. They are considered to be one of the most promising nanomaterials with the 
capability of delivering drugs to cancerous cells,[25,26] they were also used for gene therapy 
and lymphatic targeted chemotherapy.[26] The covalent bond of carbon with oxygen, 
hydrogen, and nitrogen allows easy routes for functionalization of carbon surfaces with 
organic or biological molecules.[27] Moreover, their strong optical absorbance in the near-
infrared (NIR) region is useful for photothermal ablation of tumors.[28--30] They have the 
ability of heat release in a radiofrequency field which can be used to produce thermal 
cytotoxicity in malignant cells.[31] Therefore, they can be used for photothermal,[32--35] and 
photodynamic therapy.[26,36] Furthermore, their unique optical properties, such as fluorescence 
and Raman scattering, make them useful for optical imaging and sensing applications. They 
have been used as contrast agents for echography, photoacoustic tomography, photothermal 
and Raman imaging.[37,38] 
This review focuses primarily on the description of individual types of carbon 
nanomaterials and their use as vehicles for anticancer drug delivery. 
3. Forms of Carbon Nanomaterials, their Structure, and Synthesis 
Carbon is the 15th most abundant element in the Earth’s crust, and the 4th most 
abundant element in the universe by mass after hydrogen, helium, and oxygen. Its unique 
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diversity of organic compounds and its uncommon ability to form polymers at the 
temperatures usually found on Earth enables this element to serve as a common element of all 
known life. It is the second most abundant element in the human body by mass (about 
18.5^%) after oxygen.[39] 
Carbon can exist in different dimensionalities: from zero- (0D) to three- (3D) 
dimensional forms. The 2D carbon can be wrapped up into 0D fullerenes, rolled into 1D 
nanotubes, or stacked into 3D graphite.[40] Based on their bonding structures, nano-carbons 
may be classified into sp2- and sp3-carbon nanomaterials. Typical sp2-carbon nanomaterials 
include 0D fullerene, 1D nanotubes (CNTs), and 2D graphene. Carbon nanoparticles or 
carbon dots are nano-clusters of amorphous carbon (or composed by small crystalline 
structures) with sizes smaller than 10^^nm and can be deemed as a type of 0D sp2-carbon 
nanomaterials. sp3-carbon nanomaterials, on the other hand, usually are nanodiamonds with 
crystal sizes in the nano-range.[41] The advents of sp2 and/or sp3 hybridized structures, such as 
fullerenes, carbon nanotubes, and conducting diamond, provide a route for surface 
modification.[42] Different allotropes of carbon are shown in Figure^^1<figr1>. The 
classification of dimensionality is based on the number of dimensions that are not confined to 
the nanoscale range (e.^g. whereas in a 0D system, all the dimensions are at nanoscale range, 
2D nanostructures have two dimensions outside of the nanometric size range.[43] 
Moreover, techniques have also been developed that have successfully completed the 
construction of so-called aligned carbon nanotube ropes (CNTRs)[44--47] with various length of 
the rope up to tens of µm.[48,49] CNTRs hold promise for next generation of chemical 
sensors as well as drug delivery systems.[50] 
3.1. Activated Carbon 
Activated carbon (AC), also known as charcoal, is an important member of the 
family of carbon materials. It has an amorphous structure, is chemically stable and is 
produced from a variety of carbonaceous source materials such as bamboo, wood, coconut 
shells and coal.[51] Thanks to its strong potential and bio-friendly nature, AC has attracted 
great attention for medical applications[52--57] e.^g. as a therapeutic agent for treating 
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overdoses or acute toxicity through orally ingested drugs, such as diethylcarbamazine[58] and 
acetaminophen,[59] or even in severe poisonings,[60] and has also been used as a drug delivery 
system.[61,62] Among carbon-based nanomaterials, AC is considered to be an ideal candidate 
as a carrier for tumor therapeutic agents.[51]  
3.2. Graphenes 
Graphene, a two-dimensional (2D) layer of sp2-bonded carbon, is composed of six-
atom rings in a honeycomb network with one-atom thickness.[63] Each carbon atom is bonded 
to three other carbon atoms, with the C<C->C bond length of 1.42^^Å, and a bond angle of 
120°. Each carbon atom forms three σ-bonds via three sp2 hybrid orbitals with three carbon 
atoms; the rest of the p-orbital forms a conjugated system with other contiguous carbon 
atoms. 
Graphite and its allotropes possess exceptional physicochemical properties, such as 
high fracture strength and Young’s modulus, excellent electrical and thermal conductivity, 
quick charge carrier mobility, large specific surface area, and good biocompatibility,[64--67] and 
therefore have been widely used in medicine and biotechnology,[68] including in sensitive 
biosensors,[68--73] drug delivery systems (DDSs),[74] and NIR fluorescence imaging 
techniques.[75--77] 
Graphene oxide (GO) is a water-soluble nanomaterial prepared via extensive 
chemical attack of graphite crystals to introduce oxygen-containing defects in the graphite 
stack,[78] followed by complete exfoliation of the solid into sheets of atomic thickness by 
either thermal or mechanical treatments.[79--81] The precise chemical structure of graphite 
oxide has been the subject of considerable debate over the years, and even to this day, no 
unambiguous model exists. This is because of sample-to-sample variability, due to the 
nonstoichiometric atomic composition as well as the lack of precise analytical techniques for 
characterizing this material.[82] Based on a recently proposed model, GO sheets are composed 
of planar, graphene-like aromatic domains of random sizes interconnected by a network of 
cyclohexane-like units in chair configuration which are decorated by hydroxy, epoxy, ether, 
diol, and ketone groups.[83] 
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The optical properties of graphene and GO can facilitate medical imaging. The novel 
graphitic nanostructures, combined with multi-functionalities including biocompatibility, 
photoluminescence and drug loading and delivery, suggest promising medical applications of 
graphene materials.[84] 
Lu et^^al.[85] demonstrated the ability of water-soluble GO as a platform for the 
sensitive and selective detection of biomolecules, such as DNA and proteins, in clinical 
treatment. GO can bind dye-labeled ssDNA (single-stranded DNA) resulting in quenching the 
fluorescence of the dye. Compared to CNTs, GO is due the low cost and large production 
scale a promising material for designing biosensors. 
The synthesis methods of graphene can be divided into two categories: top-down and 
bottom-up organic synthetic approaches.[86] To the top-down methods belong 1) mechanical 
exfoliation, 2) chemical oxidation/exfoliation followed by reduction of graphene derivatives 
such as graphene oxide. While the bottom-up methods include: 1) epitaxial growth on silicon 
carbide and other substrates, 2) chemical vapor deposition (CVD), and 3) arc discharging 
methods.[87] The most common approach for preparing graphene and GO is the Hummers 
method,[78] in which GO is obtained by adding graphite and NaNO3 to concentrated H2SO4, 
followed by KMnO4 as the strong oxidizing agent to oxidize the graphite to GO; 30^% H2O2 
is then added to reduce the remnant oxidizing agent and obtain GO. 
3.3. Carbon Nanofibers and Nanotubes 
Carbon nanofibers (CNFs) are morphologically cylindrical or conical structures[27] 
with diameters in the range of 100--300^^nm and lengths of a few micrometers (up to 
200^^μm).[88] The internal structure of CNFs varies and comprises different arrangements of 
modified graphene sheets. CNFs consist of stacked, curved graphite layers that form cones or 
cups. The stacked-cone structure is often referred to as a ‘herringbone’, whereas the stacked 
cup structure is referred to as a ‘bamboo’ type.[27] 
CNFs can be classified into two kinds: highly graphitic and lowly graphitic ones.[88] 
The former can be prepared either by a catalytic vapor-grown procedure with a metal catalyst 
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floating in the reaction media[89--99] or by catalytic CVD with the metal catalyst on a 
support.[100--107] 
Vapor-grown carbon fibers possess an extraordinarily high tensile modulus, tensile 
strength, and high electrical and thermal conductivity. With the decreasing diameter of a 
vapor-grown carbon fiber, the mechanical properties improve. When the fiber reaches a 
threshold value of 1^^μm, which distinguishes the transition from fibers to nanofibers, this 
improvement becomes more pronounced.[108] The usual diameter of prepared vapor-grown 
carbon nanofibers ranges from 15^^nm to 100^^nm. They are continuous with hollow cores 
and morphologically resembles multi-walled carbon nanotubes (MWCNTs).[109] Their 
stiffness and strength in combination with outstanding transport properties enable to develop 
multifunctional nanofiber composites with excellent physical and mechanical properties.[110] 
CNFs have a cylindrical shape like CNTs but possess different structural and textural 
characteristics.[88] The main feature distinguishing nanofibers from nanotubes is the stacking 
of graphene sheets with varying cross-sectional shapes and cone angles (α).[27] Nanofibers can 
have different internal structure -- graphene layers are arranged as concentric cylinders, nested 
truncated cones, segmented structures, or stacked coins.[109] 
The difference between CNF and CNT is represented by Figure^^2<figr2>. There are 
two definitions of CNT and CNF. The first one is based on morphology, the other on the 
structure. In the morphological definition, which is more common, CNT is defined as any 
graphitic carbon material of a nanometric size possessing a tubular shape, i.^e., a cylinder 
with a tubular cavity. According to this definition, the main discrepancy between a nanotube 
and a nanofiber is the absence of a hollow cavity for the latter.[111] The second definition 
defines it as a nested coaxial array of single-wall nanotubes, each nanotube being formed by a 
graphene sheet rolled into a cylinder of nanometer size diameter.[112] 
Carbon nanotubes (CNTs), discovered by Iijima in 1991, are novel-type synthetic 
nanomaterials with distinct hollow and cylindrical structure.[113] The nanometer-scale 
structure of CNTs is based on a graphene cylinder, a few nanometers in diameter, which can 
range in length from a few micrometers to millimeters.[114] CNTs can be looked at as single 
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molecules, regarding their small size (~nm in diameter and ~µm length), or as quasi-one-
dimensional crystals with translational periodicity along the tube axis. There are infinitely 
many ways to roll a sheet into a cylinder, resulting in different diameters and microscopic 
structures of the tubes. These are defined by the chiral angle, the angle of the hexagon helix 
around the tube axis.[115] 
The rolled arrangement from layers of graphene sheets[113] can be structured as single-
layered (single-walled carbon nanotubes SWCNTs), two-layered (double-walled carbon 
nanotubes, DWCNTs), as well as triple-walled carbon nanotubes (TWCNTs) or multiple 
layers (multi-walled nanotubes MWCNTs).[116] (Figure^^3<figr3>). 
A SWCNT consists of one cylindrical graphene sheet, whereas MWCNT are 
composed of several nested cylinders with an interlayer spacing of 0.34--0.36^^nm that is 
close to the typical spacing of turbostratic graphite. There are many possibilities to form a 
cylinder with a graphene sheet.[117] The three most common configurations are shown in 
Figure^^4<figr4>. One can roll up the sheet along one of the symmetry axis: this gives either 
a zigzag tube or an armchair tube. It is also possible to roll up the sheet in a direction that 
differs from a symmetry axis: one obtains a chiral nanotube, in which the equivalent atoms of 
each unit cell are aligned on a spiral. Besides the chiral angle, the circumference of the 
cylinder can also be varied. The whole family of nanotubes is classified as zigzag, armchair, 
and chiral tubes of different diameters.[118] 
Chemically functionalized SWCNTs have shown promise in tumor-targeted 
accumulation in mice exhibiting biocompatibility, excretion, and little toxicity.[119] The most 
important procedures for SWCNTs synthesis include electric arc discharge, laser ablation and 
catalytic decomposition of gaseous hydrocarbons[120] as well as CVD.[120--122] 
3.4. Carbon Nanoparticles, Nanodots, Nanohorns, Nanowalls, and Nanomesh 
Fluorescent carbon nanoparticles (CNPs) are a potential technological alternative 
due to their high water solubility, flexibility in surface modification with various chemicals, 
excellent biocompatibility, good cell permeability, and high photostability.[123,124] CNPs could 
be utilized both as nontoxic drug delivery system and bio-imaging.[125] Fluorescent CNPs 
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have a size of 2--6^^nm and can be synthesized for example via nitric acid oxidation of 
carbon soot.[126] 
Carbon nanodots (CNDs) belong to the new class of nanocarbons, which possess 
several advantages compared to carbon nanotubes. They can be synthesized from different 
biological resources via simple one-step hydrothermal treatment.[127] Graphene quantum 
dots (GQDs) can be synthesized by acidic oxidation and exfoliation of pristine 
MWCNTs.[128,129] Liu et^^al.[130] synthesized highly homogeneous GQDs by using chemical 
exfoliation of graphite nanoparticles. N-doped GQD can be prepared paralyzing citric acid in 
the presence of urea.[129] 
Single-walled carbon nanohorns (SWNHs) share similar structures as SWCNTs, 
however, in the case of SWNHs, the single graphene sheets are rolled into conical, rather than 
tubular shapes. Van der Waals forces between open ends of individual SWNHs cause their 
assembling into spherical structures.[131] The size of SWNHs aggregates is about 80--
100^^nm, which is optimal for the EPR effect and favors their accumulation into the tumor 
site when administered with intravenous injection. In addition, SWNHs do not need metal 
catalysts for the synthesis. Therefore their cytotoxic effects are reduced.[132] The shape of 
SWNHs requires less energy to be endocytosed than the shape of carbon nanotubes.[131,132] 
Besides that, SWNHs have larger surface areas and internal storage spaces than carbon 
nanotubes. Stable poly[maleic anhydride-alt-1-octadecene-poly(ethylene glycol)] (C18PMH-
PEG) modified SWNHs can be prepared by sonicating pristine SWNHs with C18PMH-PEG 
for 1^^h and the resulted solution was further purified by ultrafiltration.[132] 
Carbon nanowalls (CNWs) consist of stacks of graphene sheets standing vertically 
on a substrate. They have a high aspect ratio (length to diameter), high specific surface area, 
and excellent electrical properties.[133] 
Reduced graphene oxide nanomesh (RGONM) arises from graphene oxide 
nanoplatelets after photocatalytic degradation with TiO2 nanoparticles. Graphene oxide 
nanomeshes constructed by Akhavan[15] have had approximately 61^^nm in diameter, and the 
average thickness of the sheets has been evaluated to be approximately 0.9^^nm. The average 
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size of pores was approximately 8^^nm. They have much higher NIR absorption as graphene 
oxide nanoplatelets, therefore are very suitable for photothermal therapy. 
3.5. Fullerenes 
The fullerenes represent a distinct allotrope in the family of carbon nanomaterials. 
Their unique cage-like structure and electron-deficient nature lead to fascinating properties, 
which have made them a promising focus of various research areas. The most known 
fullerene, C60, has a van der Waals diameter of 10.18^^Å,
[134] positioning it well within the 
realm of nanotechnology. The origin of the fullerenes' crucial characteristics lies in the unique 
hybridization of the strained C<C->C bonds. Whereas the carbon atoms in graphene and 
CNTs are sp2-hybridised to give hexagonal networks, and the tetrahedral network of diamond 
is sp3-hybridised, the fullerenes are formed from a network of both hexagons (1,3,5-
cyclohexatriene[134] and pentagons ([5]radialene), leading to an average hybridization of 
sp2.[135] The presence of pentagonal rings introduces a substantial amount of strain into the 
network,[136] resulting to a rehybridised 3D structure with asymmetric π orbitals and thus three 
key properties:[137] 1) they are excellent electron acceptors (C60 exhibits six reversible 
reductions),[138] 2) the exterior of the cages can be decorated using a wide spectrum of 
chemical reactions, and 3) the relative inertness of the interior of the cages facilitates the 
capture and isolation of ionic, atomic and even small molecular species.[139] Fullerenes can be 
synthesized for example by arc discharge method.[140] 
3.6. Nanodiamonds, Carbon Onions 
Nanodiamond (ND) particles evince great potential due to their shape and small size 
(from 4 to 10^^nm in diameter), large surface area as well as the content ratio of the carbon 
sp2/sp3 hybridized bonds.[141--144] NDs possess a great potential for biomedical applications, 
including their use in anticancer therapy. The use of these nanoparticles as anticancer drug 
carriers (drug delivery systems, DDSs) is the focus of many recent studies.[145--151] The 
advantage of NDs is, besides the highest biocompatibility of materials, the possibility of 
delivering the drug to a specific site, thereby maximizing the bioavailability of the drug.[152] 
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NDs may be synthesized utilizing various methods,[153] however, the most common 
cost-effective is the detonation technique.[142,154] 
Carbon onions consist of spherical closed carbon shells and owe their name to the 
concentric layered structure resembling that of an onion. Carbon onions are sometimes called 
carbon nano-onions (CNOs) or onion-like carbon (OLC). All these names represent all kinds 
of concentric shells, from nested fullerenes to small (<100^^nm) polyhedral 
nanostructures.[155] OLC can be synthesized by many different methods. One of them with a 
potential for industrial applications uses annealing in inert gases to transform ND, which is 
currently produced in ton quantities,[156] to OLC.[157] Another synthesis techniques represent 
for example arc discharge between two graphite electrodes in water[158,159] and CVD.[160] 
4. Functionalization of Carbon Nanomaterials 
Despite their unique properties, a graphene-based material rarely features the 
surface characteristics required for certain specific applications. For this reason, surface 
functionalization is essential, and researchers have devised various covalent and noncovalent 
chemistries.[161] 
Graphene sheets without functionalization are insoluble and infusible, which limits 
their application capabilities.[161] Therefore, efforts have been made to develop solution-
processable graphene oxides[162--165] and edge-functionalized graphene sheets from exfoliation 
of graphite powders.[166--168] The invasion of heteroatoms into the hexagonal carbon sheet of 
pristine graphene unavoidably results to structural and electronic distortions, leading to 
alterations of graphene properties, such as thermal stability, charge transport, Fermi level, 
bandgap, localized electronic state, spin density, optical and magnetic properties. Depending 
on the type of dopants (with particular valence and size) and their bonding configurations, 
novel or improved properties beneficial for particular applications can appear.[66] 
Functionalization can significantly improve physicochemical and biological properties 
of nanomaterials. It can enhance their stability[132] and biocompatibility,[129,132,169] improve 
colloidal stability in aqueous suspensions,[170] exhibit much higher transport capacities,[171] 
make favorable pharmacokinetic and toxicology profiles of nanomaterials,[172] evince 
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the low dark cytotoxicity and high light cytotoxicity, as well as increase their therapy 
efficiency.[21] Moreover, it can enhance activation of the immune system.[173,174] For instance, 
Barhard et^^al.[175] reported a microfluidic-free, sensitive, planar device on treated GO 
substrates to enable quick and efficient capture of Class-II MHC-positive cells from murine 
whole blood. 
Among commonly used functionalizations of carbon nanomaterials belongs 
PEGylation.[132,169,172] This surface modification can give to nanomaterials excellent 
biocompatibility, high storage capacity for anticancer drug and high photothermal conversion 
efficiency, as well as increase efficiency of the ablation of tumors.[169] Moreover, carbon 
nanomaterials modified with PEG can display higher blood circulation times and lower 
accumulation into reticuloendothelial system (RES) organs.[176] The immunologically 
modified nanostructures can be prepared using the immune-adjuvant glycated chitosan 
(GC)[173] which was formulated to enhance the activation of the immune system.[177] GC is 
biocompatible, water-soluble, and capable of increasing the concentration of cytokines as well 
as activating immune cells.[178,179] Additionally, GC can be used as a surfactant. With the 
synergistic combination of thermal laser irradiation and immunological stimulation, laser 
immunotherapy is capable of inducing an effective anti-tumor immunological response in 
late-stage metastatic cancer patients.[180] A stabilization of carbon-encapsulated magnetic 
nanoparticles in aqueous suspensions can be achieved for example by surface modification 
using polyvinyl-alcohol (PVA).[170] Nitrogen-doped GQDs (N-GQDs) which were loaded 
with the anticancer drug, methotrexate (MTX), evinced as an efficient drug delivery system. 
For removing defects from CNFs that diminish their electrical and mechanical 
properties, graphitization is one of the most effective methods used. Heat treatment to 
1800^°C evinced substantial improvement in mechanical characteristics, while higher 
temperatures lead to a slight worsening in mechanical properties probably as a result of the 
elimination of potential bonding sites caused by the elimination of the truncated edges of the 
graphene layers. The electrical and thermal properties of the resulting nanocomposites 
improved with the increasing heat-treatment temperature.[110] 
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In CNTs, the lack of solubility and the difficult manipulation in any solvents have 
imposed great limitations on their use. CNTs are fabricated as insoluble in all organic solvents 
and aqueous solutions. They can be dispersed in some solvents by sonication, but immediately 
precipitate when this process is interrupted. However, it has been reported that CNTs can 
interact with different classes of compounds.[181--189] The formation of supramolecular 
complexes enables better processing of CNTs toward the fabrication of innovative nano-sized 
devices. Moreover, CNTs can undergo chemical reactions that make them more soluble for 
their integration into inorganic, organic, and biological systems.[189] Functionalization of 
CNTs, i.^e., the attachment of appropriate chemical functionalities onto their conjugated sp2 
carbon scaffold, enables their potential applications. The derivatized CNTs exhibit improved 
properties with respect to solubility and ease of dispersion, manipulation as well as 
processibility.[190] 
The main approaches for the modification of CNTs are: 1) the covalent attachment of 
chemical groups through reactions onto the π-conjugated skeleton of CNTs, 2) the 
noncovalent adsorption or wrapping of various functional molecules, and 3) the endohedral 
filling of their empty inner cavity.[189] A typical representation of such surface modifications 
is depicted in Figure^^5<figr5>. Particular different approaches to chemical modification 
are shown in Figure^^6<figr6>. 
An interesting modification of carbon nanomaterials can also be cyclodextrins 
(CDs).[191--193] CDs have been used as complexing agents to enhance aqueous solubility of 
poorly soluble drugs, and to increase their bioavailability and stability.[194] CDs are known to 
adsorb easily onto carbonaceous supports.[191--193,195,196] Adsorption of the CDs results in a 
better dispersion of support used in the aqueous phase.[193] Since it is unlikely that CNTs or 
nanotube ropes would be the rotaxane structures with the CDs,[197] the CDs are therefore 
believed to be adsorbed at the surface of nanotube ropes by van der Waals force.[191] The 
observations of Chen et^^al.[191] demonstrated that CDs have surprisingly distinctly 
better CNT-dispersing capability. The aqueous dispersion of SWCNTs can be achieved by 
sonication with γ-cyclodextrin in deionized water. 
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Fullerenes possess unique physical and chemical properties[198] making them suitable 
for biomedical applications.[199] However, they have, like all carbon-based nanomaterials,[200] 
a low solubility (less than 0.1^^ng^∙^L<M->1) and displays a tendency for aggregation.[201,202] 
To enhance their hydrophilicity, various functionalizations can be used, e.^g., <C->OH, <C-
>COOH, <C->NH2.
[198] The fullerene core appears to be a good drug vector since it greatly 
enhances the uptake of the cationic groups by the membrane.[199] 
5. Applications of Carbon Nanomaterials in the Cancer Therapy 
Use of carbon nanomaterials in cancer therapy includes delivery of drugs[203] or 
small therapeutic molecules at target sites, using for thermal ablation of tumor cells,[204] 
photothermal,[51,205--209] and photodynamic therapies,[51,210--212] as vehicles for gene and nucleic 
acid[213,214] delivery, for theranostics and as combined therapy approach. 
5.1. Carbon Nanotubes as Carriers of Anticancer Agents 
Besides their application as mediators for photothermal and photodynamic therapies to 
directly destroy cancer cells, using combinations of light energy, without severely damaging 
normal tissue,[215] CNTs are also attractive as carriers for cancer therapy.[216] Moreover, it was 
revealed that CNTs can easily enter all sorts of cells, including mammalian, yeast, as well as 
bacteria cells.[113] CNTs have high aspect ratios and very small size, and thus they have high 
specific surface areas, related to their needle-like shapes, enabling them to adsorb onto or 
conjugate with various therapeutic molecules. The needle-like shape of CNTs also enables 
their internalization into target cells.[215] Bio-distribution studies have shown high tumor 
accumulation of functionalized SWCNTs.[19] Therefore, CNTs are considered as promising 
nanocarriers for the delivery of therapeutic agents.[215] CNTs has been widely investigated for 
delivery of antitumor agents, including drugs,[217] genes[130,218--220] or DNA,[221,222] plasmid 
DNA,[223,224] small-interfering RNA (siRNA),[23,225--228] oligonucleotides, and DNA/RNA 
aptamers.[215,229] CNTs can also deliver proteins[215] and peptides,[230] and immunotherapy 
components.[215] Sun et^^al.[84] prepared anticancer drug-loaded nano-graphene oxide (NGO) 
with high capacity, and selectively transported into specific cancer cells by antibody-guided 
targeting.[84] 
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Various options of CNT are employed as carriers of drugs, nucleic acids, and proteins, 
including the most commonly used conjugated polymers for drug and gene delivery 
which are depicted in Figure^^7<figr7>. Polymers play an integral role in drug delivery 
technology because provide controlled release of therapeutic agents in constant doses over 
long periods, cyclic dosage, and tunable release of both hydrophilic and hydrophobic 
drugs.[231] They offer protection against chemical degradation. Some nanoparticulate 
polymeric systems possess the ability to cross the blood-brain barrier. In addition, smart 
polymers are responsive to atmospheric stimuli, such as a change in temperature; pressure, 
pH, etc., making them extremely beneficial for targeted drug delivery. Moreover, some 
polymeric systems conjugated with antibodies/specific biomarkers help in detecting molecular 
targets specifically in cancers. Surface coating with thiolated PEG and Silica-PEG improves 
water solubility as well as photostability. Furthermore, surface modification of drug carriers, 
e.^g., attachment with PEG or dextran to the lipid bilayer increases their blood circulation 
time. Polymer-drug conjugates such as Zoladex, Lupron Depot, On Caspar PEG intron, are 
used in the treatment of prostate cancer and lymphoblastic leukemia. Nontoxic, biodegradable 
and biocompatible polymers are available.[232] Biodegradable polymers find widespread use in 
drug delivery as they can be degraded to non-toxic monomers inside the body.[233] 
Behnam et^^al.[218] reported that the polyethyleneimine (PEI) derivatives bound to 
CNTs retained the ability to fully condense plasmid DNA at low N/P (nitrogen to phosphate) 
molar ratios and substantial buffering capacity in the endosomal pH range. 
5.2. Carbon Nanomaterials for Anticancer Drug Delivery 
CNT-based nano-vectors, especially functionalized nanotubes, have shown strong 
potential for therapeutic drug delivery.[234] 
Through appropriate functionalization, CNTs have been used as nanocarriers for 
anticancer drugs, such as doxorubicin (DOX),[235] betulinic acid (BA),[236] MTX,[237] 
gemcitabine (GEM),[238] etoposide, paclitaxel (PTX),[239] chelerythrine,[240] camptothecin 
(CPT), carboplatin, cisplatin (CIS),[241] Pt(II), and Pt(IV).[215] 
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Tan et^^al.[236] formulated BA, a poorly water-soluble drug, in oxidized MWCNTs 
(MWCNT-COOH) for enhanced delivery efficiency into cancer cells with reduced 
cytotoxicity. The MWCNT-BA nanocomposite evinced increased anticancer activity against 
human lung cancer cell line A549 compared to human liver cancer cell line HepG2. The IC50 
for MWCNT-BA in A549 and HepG2 cells was 2.7 and 11.0^^μg^∙^mL<M->1, respectively. 
By comparing the anticancer activity of BA alone (3.5 and 15.0^^μg^∙^mL<M->1 for A549 and 
HepG2 cells), the studies clearly showed that MWCNT-BA (about 15^%wt of loaded BA) is 
more potent than the free drug (100^% of BA), with the suggested range of concentrations 
found to be <50^^μg^∙^mL<M->1.[236] 
The PLGA[poly (lactic-co-glycolic)]-coated CNTs displayed high loading efficiency 
for paclitaxel, which demonstrated in^^vitro antitumor efficacy against human PC-3MM2 
prostate cancer cells.[239] Zhang et^^al.[242] demonstrated a targeted delivery system for DOX 
based on SWCNTs derivatized with carboxylate groups and coated with a polysaccharide 
material. There are numbers of studies that display significantly improved the therapeutic 
efficacy of drug nanocarriers against different tumor models compared to the free drugs.[243--
246] 
Also, other types of carbon nanomaterials evince a strong potential for anticancer drug 
delivery. For instance, Bayda et^^al.[247] presented a simple and economical green synthesis 
using black tea as a suitable precursor for the synthesis of CNPs by nitric acid (HNO3) 
oxidation. CNPs produced by this way are non-toxic and can be utilized for multiplexing 
applications, e.^g., for efficient delivery of DOX. The biodistribution, pharmacokinetics 
profiles and kinetics of release show that CNPs -- DOX is an optimal drug delivery vector for 
cancer therapy. Kim et^^al.[248] demonstrated that mesoporous carbon nanoparticles could 
serve as a transmembrane carrier for delivering a membrane impermeable fluorescence dye 
Fura-2 through the cell membrane to release these molecules inside of live human cervical 
cancer HeLa cells. This finding opens the way for further development of mesoporous carbon 
nanoparticles as a new generation of nanodevices for transmembrane delivery and 
intracellular release applications. Gu et^^al.[249] introduced hydrophilic mesoporous carbon 
 18 
 
 
 
18 
nanoparticles as carriers for sustained release of hydrophobic anti-cancer drug -- 
camptothecin. 
Recently, magnetic GO and magnetic CNTs were ensheathed with mesoporous silica, 
for the loading and delivery of CPT. The complex of prepared nanomaterials and CPT 
evinced remarkably high cytotoxicity towards HeLa cell lines compared to the pure drug.[250] 
Sahoo et^^al.[251] functionalized MWCNTs GO by highly hydrophilic and 
biocompatible poly(vinyl alcohol) (PVA) for loading and delivery of CPT. MWCNT<C-
>PVA<C->CPT and GO<C->PVA<C->CPT evinced higher cytotoxic activity compared to 
free CPT alone, with superior proven effect in MWCNT<C->PVA<C->CPT, interestingly 
despite that GO sheets are considered to be promising materials for drug delivery due to their 
surface availability on both sides for drug binding. 
CNT drug delivery is considered to possess high efficacy of cancer therapy and using 
a low doses of drug. In another work, in^^vivo SWCNT drug delivery for tumor suppression 
in mice was introduced. Other widely used cancer chemotherapy drug -- PTX was conjugated 
to branched polyethylene glycol chains on SWCNTs. This water-soluble SWNT-PTX 
conjugate showed higher efficacy in suppressing tumor growth than clinical used Taxol in a 
murine 4T1 breast cancer model, due to prolonged blood circulation and 10-fold higher tumor 
PTX uptake by SWCNT delivery most likely through EPR effect.[119] 
Feazell et^^al.[18] derivatized amine-functionalized soluble SWCNTs with CIS prodrug 
conjugates as an anticancer drug platform for testicular cancer cells treatment. The 
cytotoxicity of the free platinum(IV) complex enhanced by >100-fold when the complex was 
attached to the functionalized SWCNTs surface. 
Nanoparticles have higher retention times in tumors than in normal tissues owing to 
the EPR effect of tumors.[252] EPR effect is a unique phenomenon of solid tumors related to 
their anatomical and pathophysiological differences from normal tissues. In contrast to normal 
tissues and organs, most solid tumors show a higher vascular density (hypervascularity).[253] 
For tumor progression, angiogenesis is a crucial factor. Angiogenic blood vessels in tumor 
tissues, unlike those in normal tissues, have gaps (Figure^^8<figr8>) as large as 600 to 
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800^^nm between adjacent endothelial cells.[254,255] This defective vascular architecture 
coupled with poor lymphatic drainage induces the EPR effect,[255,256] leading to the 
accumulation of nanocarriers at the site of tumor tissue[252] (Figure^^8<xfigr8>). The 
accumulation of nanoparticles in tumors is affected by several factors, including the size, the 
surface characteristics of the nanoparticles and the degree of angiogenesis of the tumor.[252] 
Nanocarrier-based anticancer drugs accumulate in tumor tissue by EPR effect with much 
stronger activity than the free drugs.[243] 
Besides designing of nanomaterials targeted in tumor tissue without highly 
selective semipermeable membrane barrier, nanoparticles also can be formulated to 
deliver drugs across several biological barriers.[257,258] An efficiency of antineoplastics and 
some other types of drugs are considerably limited due to their inability to cross the blood-
brain barrier (BBB). The use of nanoparticles to deliver across this barrier appears to be very 
promising. It has been found that nanoparticles can cross the BBB following the opening of 
tight junctions by hyper-osmotic mannitol, which also can provide sustained delivery of 
therapeutic agents for difficult treated diseases such as brain tumors.[259] Also Tween 80-
coated nanoparticles are able to cross the BBB.[260] Figure^^8<xfigr8> demonstrates a 
comparison of EPR effect in hepatocellular carcinoma (HCC) and the assumed EPR in 
tumor tissue with BBB. 
It was reported that macromolecules like albumin, leak out more from tumor vessels, 
the result being an augmentation of the EPR effect.[261,262] Figure^^9<figr9> demonstrates 
internalization of human serum albumin (HSA) bound to MWCNTs, which was incorporated 
into vesicles containing membrane protein Gp60. 
Despite the widespread use of drug delivery CNTs, some important issues are not 
entirely solved, such as long-term cytotoxicity in the body, lack of size uniformity during the 
synthetic process, loading deviations for drug-CNT complexes, and release controllability at 
the target point. If these limitations are overcome, it can be assumed that CNTs will become 
one of the strongest tools for cancer therapy.[215] 
6. Conclusion and Future Perspectives 
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With the global rise in the incidence of various cancers and due to the many known 
side effects of conventional therapy, it is necessary to develop new ways of more 
effective and gentler treatment of these diseases. Nanostructured materials that are able to 
circulate in the body possess high potential in this respect. Carbon nanomaterials are currently 
intensively being developed for cancer therapy, including drug and gene delivery. Despite this 
considerable progress, their widespread applications are still considered with apprehension 
due to possible toxicity risks. However, some carbon nanomaterials, like nanodiamonds, were 
found to be highly biocompatible and almost nontoxic, and as some research studies have 
shown, toxic effects of others can be reduced by their suitable chemical functionalization, 
while also increasing their biocompatibility. The appropriate functional modification also 
enables to eliminate their poor water solubility and thus to remove dispersion problems in an 
aqueous medium. Moreover, the indisputable advantage that makes the carbon nanomaterials 
quite unique is their ability to cross the membranes of many different types of cells passively. 
In addition, nanocarriers can be accumulated preferentially at tumor sites by the EPR effect, 
resulting in increased selective targeting and improved drug efficacy. All these advantages 
suggest the potential exploitation of carbon nanomaterials for drug administration. Therefore, 
a great task of scientists for the coming years will be the development of novel 
functionalization strategies for further improvement of surface characteristics of carbon 
nanomaterials that would improve the additional controlled release of the drug transported at 
the target site and would also lead to the elimination of concerns about toxicity. Overcoming 
these obstacles, carbon nanomaterials become one of the most powerful tools available for 
cancer treatment in the near future. 
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CNFs carbon nanofibers 
CNTs carbon nanotubes 
CNTRs carbon nanotube ropes 
CNPs carbon nanoparticles 
CPT camptothecin 
CVD chemical vapor deposition 
DOX doxorubicin 
DDSs drug delivery systems 
DWCNTs double-walled carbon nanotubes 
EDC (EDC · HCl) N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EPR enhanced permeability and retention 
GC glycated chitosan 
GO graphene oxide[20] 
HSA human serum albumin 
MTX methotrexate 
MWCNTs multi-walled carbon nanotubes 
NHS N-hydroxysuccinimide 
NIR near-infrared 
OLC onion-like carbon 
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PEG polyethylene glycol 
PEI polyethyleneimine 
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PSS polystyrene sulfonate 
PVP polyvinyl pyrrolidone 
PTX paclitaxel 
ssDNA single-stranded DNA 
SWNHs single walled carbon nanohorns 
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Figure^^1 The most common allotropes of carbon. Elemental carbon exists in two 
natural allotropes, graphite and diamond, which consist of extended networks of sp2- and sp3-
hybridized carbon atoms. There are also known synthetic carbon allotropes -- fullerenes, 
nanotubes and graphene.[186] Graphene is a 2D building material for allotropes of carbon 
nanomaterials. It can be wrapped up into 0D buckyball, rolled into a 1D nanotube, or stacked 
into 3D graphite.[263] sp2-carbon nanomaterials include fullerene, carbon nanotubes, and 
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graphene, while to sp3-carbon nanomaterials belong nanodiamonds.[264] Adapted from Singh 
et^^al.[87]  
 
Figure^^2 Schematic representation of CNFs and CNTs. Despite the different 
morphological structure, hollow CNF and MWCNT can be included under the term 
MWCNTs. Furthermore, according to the definition of Dresselhaus and Endo,[112] only the 
last one can be called MWCNT. Adapted from.[265] 
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Figure^^3 Types of carbon nanotubes. Adapted from[266] 
Figure^^4 Different chiralities of carbon nanotubes. CNTs structure can possess 
different chiralities: armchair, zigzag and chiral structures. 
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Figure^^5 Surface modifications of carbon nanotubes with polymers. To tailor the 
chemical nature of the nanotube's walls in order to take advantage of their unique properties, 
two main strategies for the surface modification of CNTs are used, i.^e. covalent and 
noncovalent, depending on whether or not covalent bonding between the CNTs and the 
functional groups and/or modifier molecules is involved in the modification surface 
process.[267] A covalent type of functionalization represents the covalent bond formation, and 
non-covalent one is due to the van der Waals forces only.[268] Adapted from[267] 
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Figure^^6 Various approaches for chemical functionalization of CNTs.[190,269--290] 
Two main types of functionalization, namely, a covalent one, and noncovalent[291] include a 
variety of different modifications.[285,292--304] 
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Figure^^7 The surface of CNTs. To the surface of the carbon nanotubes, various 
therapeutic agents, such as an anticancer drug, nucleic acid as well as even antibody can be 
attached. Nowadays, many types of polymers are used for drug and gene delivery. The most 
widely used polymers are shown.[218,232,305--310] NHS - N-hydroxysuccinimide; EDC 
(EDC·HCl) - N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; PVP- 
polyvinylpyrrolidone; PSS -- polystyrene sulfonate; PmPV -- poly{(m-phenylenevinylene)-
co-[(2,5-dioctyloxy-p-phenylene)vinylene]} ; PPyPV -- poly{(2,6-pyridinylenevinylene)-co-
[(2,^5-dioctyloxy-p-phenylene)vinylene]}; PAmPV - poly{(5-alkoxy-m-phenylenevinylene)-
co-[(2,5-dioctyloxy-p-phenylene)vinylene]}; PAM -- polyacrylamide; PLGA -- poly(D,L-
lactide-co-glycolide); PEG -- polyethyleneglycol; PEI – polyethyleneimine 
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Figure^^8 Targeted drug delivery and enhanced permeation and retention (EPR) effect in 
different types of tissues. A -- Targeted drug delivery to hepatocellular carcinoma (HCC) and 
illustration of EPR effect. For tumor blood vessels, a loss of smooth muscle cells, 
extracellular matrix degradation, and increased endothelial permeability are typical.[311] The 
aberrant tumor vasculature together with reduced lymphatic drainage evokes the development 
of the EPR effect,[255,256,312] leading to the accumulation of nanoparticles at the tumor site.[252] 
A targeted drug delivery system (here represented by functionalized CNTs loaded with the 
anticancer drug) uses changes in pH. The drug binds at physiological pH (pH^^7.4) and is 
only released at a lower pH typical for tumor environments.[242] B -- Targeted drug delivery 
across blood-brain-barrier (BBB) and the assumed EPR effect for CNT-based targeted drug 
delivery system. The BBB is a highly selective semipermeable membrane barrier that 
separates the circulating blood from the brain and extracellular fluid in the central nervous 
system (CNS). Nanoparticles, in contrast to free antitumor drugs, possess the ability to cross 
the BBB. Therefore they are promising for drug delivery in difficult-to-treat tumors, like brain 
tumors. The release of anticancer drug from a nanomaterial-based targeted drug delivery 
system is allowed by similar changes in brain tumor tissue like in other tumors, including a 
decrease in pH and hypoxia environment generation. 
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Figure^^9 The proposed mechanism for the internalization of HSA-CNT-mediated 
albumin receptor. Adapted from[313] Gp60 receptor -- albumin receptor; albondin; HSA -- 
human serum albumin; a -- plasma (cell) membrane; b -- cytoplasm; 1 -- caveosome; 2 -- 
early endosome; 3 -- matured (late) endosome. The assumed mechanism for the 
internalization of HSA-CNT-mediated albumin receptor that is taking place within 
hepatocellular carcinoma cells (HepG2 cells): CNT internalization involves the 
selective uptake of HSA-CNT through albumin receptors GP60. The first step is the 
formation of caveolar invaginations on the surface of the cell membrane, so-called 
caveosomes. The vesicles are then transformed into early endosomes. Matured (late) 
endosomes receive the internalized material on the route to lysosomes, usually from 
the early endosomes in the endocytic pathway, and most of the associated receptors 
circulate back into the plasma membrane. Late endosomes mediate, and the final set 
of sorting events before the material is delivered to lysosomes. Lysosomes are the last 
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of the endocytic pathway. CNTs are released within the cytoplasm-forming clusters, 
and HSA is cleaved by lysosomes.[313] 
 
 
